Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Advanced Cancer 6Melanoma 3Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Malignancies Multiple 1Lymphoid Interstitial Pneumonia 1Lung Neoplasms 1Laryngeal Diseases 1Head and Neck Neoplasms 1Glioblastoma 1Endometrial Adenocarcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 87atezolizumab 81pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Capecitabine 30Immune Checkpoint Inhibitors 29Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × linrodostat × Clear all
NCT03695250 2023-08-22

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

University of California, Davis

Phase 1/2 Terminated
8 enrolled 11 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡